Microdose Journal

Scientific News, Journal Papers, Studies for Microdosing for Mental Health

Menu
  • About MicrodoseJournal.com
  • Conferences
  • Contact
  • Find Psychedelic Therapy Providers:
  • News
  • Psychedelic Studies & Research Centers
  • Retreats
  • Scientific Papers
  • Video
Menu

Production Options for Psilocybin: Making of the Magic

Posted on January 22, 2020January 22, 2020 by Research

Chemistry – A European Journal, 25(4), 897-903, January 2019
https://doi.org/10.1002/chem.201802758

Authors

  1. Janis Fricke – Department Pharmaceutical Microbiology, Hans-Knöll-Institute Friedrich-Schiller-Universität, Beutenbergstrasse 11a, 07745, Jena, Germany
  2. Claudius Lenz – Department Pharmaceutical Microbiology, Hans-Knöll-Institute Friedrich-Schiller-Universität, Beutenbergstrasse 11a, 07745, Jena, Germany
  3. Jonas Wick – Department Pharmaceutical Microbiology, Hans-Knöll-Institute Friedrich-Schiller-Universität, Beutenbergstrasse 11a, 07745, Jena, Germany

Abstract

The fungal genus Psilocybe and other genera comprise numerous mushroom species that biosynthesize psilocybin (4-phosphoryloxy-N,N-dimethyltryptamine). It represents the prodrug to its dephosphorylated psychotropic analogue, psilocin. The colloquial term “magic mushrooms” for these fungi alludes to their hallucinogenic effects and to their use as recreational drugs. However, clinical trials have recognized psilocybin as a valuable candidate to be developed into a medication against depression and anxiety. We here highlight its recently elucidated biosynthesis, the concurrently developed concept of enzymatic in vitro and heterologous in vivo production, along with previous synthetic routes. The prospect of psilocybin as a promising therapeutic may entail an increased demand, which can be met by biotechnological production. Therefore, we also briefly touch on psilocybin’s therapeutic relevance and pharmacology.More

Acknowledgements

We are grateful to Robert Kargbo (Usona Institute, Madison, WI) for valuable comments on the manuscript. C.L. acknowledges a doctoral fellowship by the International Leibniz Research School (ILRS) for Microbial Interactions. Work in D.H.’s laboratory on psilocybin biosynthesis is supported by the Deutsche Forschungsgemeinschaft (DFG, grant HO2515/7‐1). D.H. is also supported by the Collaborative Research Center ChemBioSys (grant SFB1127) and by the excellence graduate school Jena School for Microbial Communication (JSMC).

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

About This Site

The Microdose Journal provides scientific studies and articles relating to the phenomenon of microdosing for the improvement of mental health.  It is also a resource for major study centers, conferences, and therapy centers that utilize psychedelics.

Recent Posts

  • A Review of LSD Treatment in Alcoholism
  • Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study
  • The entropic brain: a theory of conscious states informed by neuroimaging research with psychedelic drugs
  • The ethics of psychedelic research in disorders of consciousness
  • Psychedelic Support
  • Santa Cruz, California City Council Approves Decriminalization Measure Measure for Psychedelics
  • Safety, tolerability, pharmacokinetics, and pharmacodynamics of low dose lysergic acid diethylamide (LSD) in healthy older volunteers
  • Current perspectives on psychedelic therapy: use of serotonergic hallucinogens in clinical interventions
  • Sub-Acute Effects of Psilocybin on Empathy, Creative Thinking, and Subjective Well-Being
  • The Associations of Naturalistic Classic Psychedelic Use, Mystical Experience, and Creative Problem Solving
© 2023 Microdose Journal | Powered by Minimalist Blog WordPress Theme